If not TIP, then what?
Families searching for alternatives usually hit one of three walls: the waitlist, the price, or the travel. Each wall has different doors.
Four real alternatives, mapped by fit rather than ranked. Latitude — the other leading in-person clinic: about a dozen locations across California and New York, in-network insurance for visits, a shorter published active phase. Standard OIT at a local allergist — published protocols offered off-label at specialist practices in most states; ask allergists near you directly, since directories are incomplete. Xolair — the only FDA-approved food allergy medication left: reduces reaction severity from accidental exposure, does not desensitize, and can complement immunotherapy. The at-home route (Curex) — the only fully at-home program: gentler sublingual treatment via telemedicine, higher graduation rate, typically $10,000+ cheaper over a course. A history of anaphylaxis or severe asthma routes to in-person care regardless. We are on this list — read accordingly.
Medically reviewed by Dr. Chet Tharpe, M.D. · Last reviewed September 2026
The map
Four doors, by the wall you hit
| You hit… | First door to try | Why |
|---|---|---|
| The waitlist | Latitude, or local OIT allergists | A dozen Latitude clinics and distributed OIT practices intake independently of FAI’s list — and gentler at-home treatment can start while any list moves. |
| The price | Local OIT; at-home SLIT | Standard protocols without destination-program pricing; the at-home route typically saves $10,000+ over a course. |
| The travel | At-home SLIT; Xolair locally | One removes geography from treatment entirely; the other is administrable near home and reduces accidental-exposure severity. |
| Severity gates (anaphylaxis, asthma) | In-person assessment, full stop | Candidacy for any program — theirs or ours — is a clinical decision that starts face to face. |
Competitor figures are what each provider published on its own site or what patients reported publicly, dated where checked. Prices and policies change — confirm current figures with each provider, including us, before enrolling.
Disclosure
Where we stand on this list
Curex is the only fully at-home food allergy program. Testing is done through local labs, at-home phlebotomy, or self-collection kits; doctors see patients via video visit or text message; and Allergychoices pharmacy ships the prescription treatment directly to the patient. The treatment is more gentle and generally a bit slower, but it has a much higher graduation rate because patients don’t drop out from negative side effects — and patients can generally save more than $10,000 over the course of treatment.
Curex competes in this market — we run the only fully at-home food allergy program — so read this page as a competitor’s honest summary of the public record and verify against the sources. The deeper dives: the treatment landscape, the geography of access, and what each protocol asks of a week.
❓Frequently Asked Questions
Latitude — the other leading in-person clinic: proprietary SLIT+OIT protocols, supervised challenges, both coasts covered, in-network billing for visits, and a published active phase of 6–12 months. The comparison page lays the two side by side. For a family specifically drawn to aggressive supervised desensitisation, this is the first alternative to price.
Not the proprietary protocol — but standard oral immunotherapy, published and long-practised, is offered off-label at specialist practices in roughly 35 states, often at materially lower cost than destination programs. Directories are incomplete: the highest-yield move is calling allergists within your radius and asking specifically whether they run OIT for your allergen.
Since Palforzia’s withdrawal in July 2026, omalizumab (Xolair) is the only FDA-approved food allergy medication: injections every 2–4 weeks that reduce the severity of reactions to accidental exposure. It does not desensitize — avoidance continues — but it is insurance-billable, available far from specialty centres, and clinics sometimes pair a biologic with immunotherapy so patients can tolerate meaningful doses during treatment. The biologic protects during treatment; the immunotherapy modifies the disease.
It is the default many families are left with, and the one option with no upside: the allergy stays exactly as dangerous, and the daily vigilance never ends. Immunotherapy — clinic or at-home — is the only path that modifies the disease itself. If every structured program feels out of reach, start smaller: proper testing, an epinephrine action plan, and one conversation with a clinician about which road is realistic for your family.
If you experience sudden difficulty breathing, throat swelling, or other signs of anaphylaxis, call 911. A prescribed epinephrine auto-injector is the first-line treatment — not antihistamines.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Keep reading
- Is Curex legit?The company, the evidence, and the concerns worth knowing — including full context on the 2025 FDA warning letter.Read
- How Curex worksThe treatment process end to end, from at-home testing to daily drops.Read
- Curex reviewsWhat patients actually report — both clusters, including the complaints.Read
- Is Curex worth the money?Plan pricing against allergy-shot costs, and who it is not worth it for.Read
- Evidence & guidelinesWhat the FDA approved, what the AAAAI/ACAAI practice parameter does and does not endorse, and what has been added since.Read
- Providers comparedCurex, Wyndly and Nectar on published prices, guarantees and evidence — including where a competitor is ahead.Read